| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T337 |
0-206 |
Sentence |
denotes |
Given the robust immunomodulatory nature of type I IFNs, uninfected or early symptomatic patients would benefit the most from this therapy to prevent exacerbating immunopathology at later stages of disease. |
| T338 |
207-288 |
Sentence |
denotes |
Numerous clinical trials have been initiated investigating type I IFNs (Table 1). |
| T339 |
289-509 |
Sentence |
denotes |
A large study (NCT04320238) of ~3,000 medical staff allocated participants to two trial arms: (i) low-risk (non-isolated wards or laboratories) or (ii) high-risk (isolated wards in direct contact with COVID-19 patients). |
| T340 |
510-703 |
Sentence |
denotes |
In addition to the IFN-α-1b nasal drops, high-risk medical staff will also receive the immune-modulating TLR activator, thymosin α1, which indirectly activates NK cells through pDCs (176, 177). |
| T341 |
704-858 |
Sentence |
denotes |
Interestingly, reports in SARS-CoV-1 studies showed that IFN-β therapy had a 50-fold greater anti-viral activity in Vero cells than IFN-α treatment (178). |
| T342 |
859-1339 |
Sentence |
denotes |
Promising results have been published from a Phase II study (NCT04276688) (179), showing that complementing lopinavir-ritonavir and ribavirin with subcutaneous IFN-β-1b in mild-to-moderate COVID-19 patients is safe with no serious adverse events reported in the triple combination therapy group, and highly effective, with significant and clinically meaningful reductions in time to complete alleviation of symptoms, hospital length of stay, and time to negative viral load (179). |
